| abstract |
The present application is directed to transdermal formulations for the delivery of berberine compounds to a subject for the treatment of berberine-responsive diseases. In particular, the transdermal formulation comprises: (a) an aqueous phase comprising water and at least one water soluble emulsion stabilizer; (b) an oil phase comprising at least one emulsifier, at least one oil soluble emulsion stabilizer, at least one emollient comprising at least one flavonoid and at least one other emollient; wherein the oil and aqueous phases form an emulsion; (c) an external phase comprising at least one flavonoid containing-extract, at least one phospholipid-complexed flavonoid and at least one source of berberine or analog or derivative thereof; and optionally (d) at least one preservative phase. |